Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
2011
Chronic infection with hepatitis C virus (HCV) is a major public health problem, with nearly 170 million infected individuals worldwide. Current treatment for chronic infection is a combination of
pegylatedIFN-α2 and
ribavirin(RBV); however, this treatment is effective in fewer than 50% of patients infected with
HCV genotype1 or 4. Recent studies identified the chemokine
CXCL10(also known as IP-10) as an important negative prognostic biomarker. Given that
CXCL10mediates chemoattraction of activated lymphocytes, it is
counterintuitivethat this chemokine correlates with therapeutic nonresponsiveness. Herein, we offer new insight into this paradox and provide evidence that
CXCL10in the plasma of patients chronically infected with HCV exists in an antagonist form, due to in situ amino-terminal truncation of the protein. We further demonstrated that
dipeptidyl peptidaseIV (DPP4; also known as CD26), possibly in combination with other proteases, mediates the generation of the antagonist form(s) of
CXCL10. These data offer what we believe to be the first evidence for
CXCL10antagonism in human disease and identify a possible factor contributing to the inability of patients to clear HCV.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
44
References
157
Citations
NaN
KQI